Aaru

Simile raises a $200M Series B at a $2B valuation just 5 months after a $100M Series A, with Greenoaks leading and investors including Index Ventures, CVS Health Ventures, and others; CVS is also a marquee customer for its synthetic-user product.

Aaru, an AI synthetic research startup, raised a Series A led by Redpoint at a headline $1B valuation with a round size above $50M; ARR is under $10M.